Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-06-19

Clinical Trial Update: A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention. [Phase 2]

View source ↗

Summary

Phase 2 trial assessing long-term safety and efficacy of erenumab (AMG 334) for chronic migraine prevention is completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • erenumab (erenumab)

Snippet

Sponsor: Amgen | Conditions: Treatment for Prevention of Chronic Migraine | Phase 2 | Status: COMPLETED | Results posted: 2018-06-19